PT - JOURNAL ARTICLE AU - Geovanna Cárdenas AU - Francisco Novillo AU - Shuheng Lai AU - Héctor Fuenzalida AU - Francisca Verdugo AU - Gabriel Rada TI - Oxymetazoline for the treatment of rosacea-associated persistent facial erythema. Systematic review and meta-analysis protocol AID - 10.1101/2020.05.25.20111344 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.25.20111344 4099 - http://medrxiv.org/content/early/2020/05/26/2020.05.25.20111344.short 4100 - http://medrxiv.org/content/early/2020/05/26/2020.05.25.20111344.full AB - Objective The objective of this systematic review is to assess the impact of oxymetazoline in patients with moderate to severe rosacea.Data Sources We will conduct a comprehensive search in PubMed/Medline, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), Lilacs, the International Clinical Trials Registry Platform (ICTRP), ClinicalTrials.gov, US National Institutes of Health (NIH) and grey literature, to identify all relevant randomized controlled trials regardless of language or publication status (published, unpublished, in press and in progress).Eligibility criteria for selecting studies and methods We will include randomized trials evaluating the effect of oxymetazoline in patients with moderate to severe rosacea. Two reviewers will independently screen each study for eligibility, data extraction, and assess the risk of bias. We will pool the results using meta-analysis and will apply the GRADE [1] system to assess the certainty of the evidence for each outcome.Ethics and Dissemination No ethics approval is considered necessary. The results of this review will be widely disseminated via peer-reviewed publications, social networks and traditional media.Protocol and Registration This protocol was adapted to the specificities of the question assessed in this review and registered to PROSPERO with the ID CRD42020150262.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was not commissioned by any organization and did not receive external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:As researchers will not access information that could lead to the identification of an individual participant, obtaining ethical approval was waived.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data related to the project will be available on the final publication.